(Q62809133)
Statements
A Phase 2B Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety and Efficacy of BMS-986036 (PEG-FGF21) in Adults With Nonalcoholic Steatohepatitis (NASH) and Compensated Liver Cirrhosis (English)
0 references
4 May 2018
0 references
9 January 2020
0 references
100
0 references
18 year
0 references
75 year
0 references